TriangleNCT02872103 · CITED IN SOURCE DOCUMENTS
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2021-05-05
This is a randomized, double-blind and placebo controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with stage II-IV breast cancer receiving chemotherapy treatment.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo
The Duration in Days of Grade 4 (Severe) Neutropenia (ANC < 0.5 × 10^9/L) for Chemotherapy Cycles 2, 3, and 4, and Over All Cycles.
The Duration in Days of Grade 2 (Mild), Grade 3 (Moderate) and 4 (Severe) Neutropenia Over All Cycles.
Number of Participants With Febrile Neutropenia (FN) for Each Chemotherapy Cycle and Over All Cycles
Number of Participants With Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles.
The Time in Days to ANC Recovery Post Nadir for Each Chemotherapy Cycle and Over All Cycles; Recovery Defined as an ANC ≥ 2.0 × 10^9/L After the Expected ANC Nadir.
The Depth of the ANC Nadir for Each Chemotherapy Cycle and Over All Cycles.
Number of Participants With Infections for Each Chemotherapy Cycle and Over All Cycles.
Number of Participants With Use of Antibiotics and Pain Medications
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial. 2. Females ≥ 18 years of age and \< 75 years of age. 3. Diagnosed with Stage II-IV breast cancer. 4. Subject is scheduled to undergo 4 cycles of TA chemotherapy (docetaxel, doxorubicin, 75, and 60 mg/m2, respectively). 5. ECOG Performance status of ≤ 2. 6. White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet count ≥ 150 × 109/L. 7. Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN. 8. All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial. Exclusion Criteria: 1. Subject is \<18 or ≥ 75 years of age. 2. Disease progression has occurred while receiving a taxane regimen. 3. Subject has undergone radiation therapy within 4 weeks of enrollment. 4. Subject has undergone bone marrow or stem-cell transplantation. 5. Subject has a history of prior malignancy other than breast cancer that is NOT in remission. 6. Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e. lithium) within 6 weeks of the screening period are excluded. 7. Subject has had chemotherapy within 365 days of screening. 8. Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test. 9. History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure. 10. Unwillingness to participate in the study. 11. Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events. 12. Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment. 13. Any condition, which can cause splenomegaly. 14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease. 15. ALT, AST, alkaline phosphatase, total bilirubin ≥ 2.5 upper limit of normal. 16. Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C. 17. Women who are pregnant or breast-feeding. 18. Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder. 19. Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated. 20. Subjects with Sickle Cell disease 21. Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.
- healthy Volunteers
- false
- maximum Age
- 74 Years
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
- intervention Names
- Drug: F-627
- label
- F-627
- type
- EXPERIMENTAL
- description
- Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
- intervention Names
- Drug: F-627
- Drug: Placebo
- label
- Placebo
- type
- PLACEBO_COMPARATOR
- interventions
- arm Group Labels
- F-627
- Placebo
- description
- F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
- name
- F-627
- type
- DRUG
- arm Group Labels
- Placebo
- description
- Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
- name
- Placebo
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- QUADRUPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 122
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Subjects will be randomized to F-627 or Placebo at 2:1 ratio. About 24 hours after chemotherapy, subjects will either receive 20mg fixed dose F-627 or Placebo. The subject's absolute neutrophil count (ANC) will be monitored each day post chemotherapy administration until the ANC level exceeds 2.0x10\^9/L, then the value will be monitored every three days until the next chemotherapy cycle is entered. The duration of grade 4 neutropenia (ANC \<0.5x10\^9/L) in this cycle is the primary efficacy endpoint.
- measure
- The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo
- time Frame
- The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks
- secondary Outcomes
- description
- The duration of severe neutropenia will be measured for each patient during chemotherapy cycle 2-4 and over all cycles. Each chemotherapy is expected to last 21 days.
- measure
- The Duration in Days of Grade 4 (Severe) Neutropenia (ANC < 0.5 × 10^9/L) for Chemotherapy Cycles 2, 3, and 4, and Over All Cycles.
- time Frame
- Over all 4 cycles, about 12 weeks
- description
- The duration in days of mild, moderate and severe neutropenia will be recorded for 4 chemotherapy cycles. Grade 2 neutropenia is when a patient's ANC\<1.5x10\^9/L, Grade 3 neutropenia is when a patient's ANC\<1.0x10\^9/L, and Grade 4 neutropenia is when a patient's ANC \<0.5x10\^9/L.
- measure
- The Duration in Days of Grade 2 (Mild), Grade 3 (Moderate) and 4 (Severe) Neutropenia Over All Cycles.
- time Frame
- 4 chemotherapy cycles, about 12 weeks
- description
- Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of \>38.0°C (100.4°F) sustained for \>1 hour and ANC \< 0.5 x 10\^9/L
- measure
- Number of Participants With Febrile Neutropenia (FN) for Each Chemotherapy Cycle and Over All Cycles
- time Frame
- 4 chemotherapy cycles, about 12 weeks
- description
- The number of subjects with grade 2, 3 and 4 neutropenia will be recorded for all 4 chemotherapy cycles.
- measure
- Number of Participants With Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles.
- time Frame
- 4 chemotherapy cycles, about 12 weeks
- description
- The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded. Recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10\^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration).
- measure
- The Time in Days to ANC Recovery Post Nadir for Each Chemotherapy Cycle and Over All Cycles; Recovery Defined as an ANC ≥ 2.0 × 10^9/L After the Expected ANC Nadir.
- time Frame
- 4 chemotherapy cycles, about 12 weeks
- description
- The depth of ANC nadir for each cycle is the minimal ANC value (× 10\^9/L ) for a patient in each chemotherapy cycle
- measure
- The Depth of the ANC Nadir for Each Chemotherapy Cycle and Over All Cycles.
- time Frame
- 4 chemotherapy cycles, about 12 weeks
- description
- The number of subjects with infections for each arm of the study will be recorded for each and all 4 chemotherapy cycles.
- measure
- Number of Participants With Infections for Each Chemotherapy Cycle and Over All Cycles.
- time Frame
- 4 chemotherapy cycles, about 12 weeks
- description
- Antibiotics and pain medications use will be recorded for each chemotherapy cycle and overall cycles
- measure
- Number of Participants With Use of Antibiotics and Pain Medications
- time Frame
- 4 chemotherapy cycles, about 12 weeks
Full study description
- brief Summary
- This is a randomized, double-blind and placebo controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with stage II-IV breast cancer receiving chemotherapy treatment.
- detailed Description
- This is a randomized, multi-center, single dose, double-blind, placebo controlled phase III study of the efficacy and safety of once-per-cycle of F-627 in women with stage II-IV breast cancer who are receiving myelotoxic TA chemotherapy treatment (Taxotere (docetaxel) + Adriamycin(doxorubicin)). F-627 is designed to treat neutropenia, an abnormally low number of neutrophils (a type of white blood cell) in the blood. Neutropenia is often seen in cancer patients receiving myelotoxic chemotherapy. The primary objective of this study is to evaluate the efficacy and safety of single fixed dose of F-627 in breast cancer patients experiencing myelotoxic chemotherapy in comparison to placebo. F-627 or placebo is to be administered subcutaneously 24 hours after chemotherapy in each 21-day cycle of chemotherapy treatment (up to 4 cycles). Patients randomized to placebo arm will receive F-627 except in cycle 1. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC \< 0.5 x 10\^9/L) observed in chemotherapy cycle 1.
Source references
- references
- citation
- Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023 Dec 16;32(1):34. doi: 10.1007/s00520-023-08176-6.
- pmid
- 38103088
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-aa1a01ca931e94268927
- requested nct id
- NCT02872103
- primary nct id
- NCT02872103
- source kind
- fda_spl_label
- source record id
- 523867f4-dbc4-1258-e063-6394a90a3145
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 005e801466d334500775f40d43137707429f1fa3ee7fda6c883e32c99696bc62
- payload
- application numbers
- BLA761134
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-aa1a01ca931e94268927
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02872103
- occurrences
- context exact
- ia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs was evaluated in two randomized, controlled studies. Study GC-627-04 [NCT02872103] was a randomized, double-blind, placebo-controlled study that employed doxorubicin 60 mg/m 2 and docetaxel 75 mg/m 2 administered every 21 days for up to 4 cy
- end
- 291
- exact text
- NCT02872103
- start
- 280
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/44/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 523867f4-dbc4-1258-e063-6394a90a3145
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 89396d4651acb7c34f9b77ada7ecabfa52eb42984348900650971c9ca846426e
- spl effective time
- 20260519
- spl set id
- 290ed754-758c-9cae-e063-6294a90ae68b
Preserved source evidence · Not medical advice